Collplant Biotechnologies

Collplant Biotechnologies OCF Margin

The Operating Cash Flow Margin of Collplant Biotechnologies (CLGN) as of Nov 1, 2026 is -397.26 %. In the previous year, Operating Cash Flow Margin was -2,736.50 % — a change of -85.48% (higher).

OCF Margin

-397.26 %

YoY

-85.48%

Last updated:

Operating Cash Flow Margin of Collplant Biotechnologies is 2025 -397.26 % . Operating Cash Flow Margin of Collplant Biotechnologies was 2024 -2,736.50 % . It decreases by -85.48% higher compared to the previous year.

The Collplant Biotechnologies OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-25.42 USD
Jan 1, 2019
-246.03 USD
Jan 1, 2020
-72.53 USD
Jan 1, 2021
15.99 USD
Jan 1, 2022
-4,581.27 USD
Jan 1, 2023
-25.21 USD
Jan 1, 2024
-2,736.50 USD
Jan 1, 2025
-397.26 USD
The Collplant Biotechnologies OCF Margin history
YEAROCF MarginYoY
-397.26 %-85.48%
-2,736.50 %+10,753.91%
-25.21 %-99.45%
-4,581.27 %-28,750.80%
15.99 %-122.05%
-72.53 %-70.52%
-246.03 %+868.03%
-25.42 %-97.54%
-1,034.76 %-84.37%
-6,618.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Collplant Biotechnologies Stock analysis

What does Collplant Biotechnologies do? CollPlant Biotechnologies Ltd. develops and markets regenerative medicine products based on plant-derived collagen type I (rhCollagen) for tissue repair and organ bioprinting. The company focuses on medical aesthetics and tissue regeneration applications, targeting healthcare providers and research institutions seeking advanced bioprinting solutions. Its core technology enables the production of collagen without animal sources, addressing market demands for ethical and sustainable biomaterials. The firm's products include bioprinting solutions for tissue and organ production, which are sold to medical research organizations and healthcare facilities. CollPlant's technology differentiates itself through plant-based collagen, appealing to clients prioritizing eco-friendly and animal-free medical solutions. This approach aligns with growing industry trends toward sustainable regenerative medicine practices. CollPlant Biotechnologies Ltd. generates revenue through the sale of its bioprinting technologies and collagen-based medical products. The company's target segments include regenerative medicine researchers, tissue engineering specialists, and medical aesthetics providers who require advanced biomaterials for their applications. These segments value the company's plant-derived collagen technology for its ethical sourcing and performance in tissue repair applications. Collplant Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Collplant Biotechnologies stock

Operating Cash Flow Margin of Collplant Biotechnologies is -397.26 % in 2025.

Operating Cash Flow Margin of Collplant Biotechnologies changed from -2,736.50 % to -397.26 %, representing a -85.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Collplant Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Collplant Biotechnologies with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Collplant Biotechnologies

All Key Metrics — Collplant Biotechnologies